The article Atai Announces Disappointing Results in PCN-101 Phase 2a Trial was originally published on Microdose. The industry has been waiting for these...
Atai plans to continue working with its compound despite the setback. The post Atai Life Sciences Ketamine Treatment for Depression Fails in Mid-Stage...
PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of...
Universal Ibogaine (TSX.V: IBO), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered...
The article Top 3 Psychedelic Storylines to Watch in 2023 was originally published on Microdose. 2022 was a milestone year for the psychedelic industry...
Some analysts have called the industry's business model problematic. The post Despite Psychedelic Industry Buzz, Some Have Crashed Already appeared first...
The article 2022 Review: 3 Trials Pushing Boundaries of Psychedelic Medicine was originally published on Microdose. In my most recent article, The Top...
The article 2022 End of Year Review: Small Pharma was originally published on Microdose. Continuing our end-of-year review, we’ll take a moment to update...
From a new congressional caucus to the protection of indigenous knowledge, leaders in the field reflect on this year's significant events in the psychedelic...
The article 2022 End of Year Review: atai Life Sciences was originally published on Microdose. The end of the year is a convenient time to look...